Trials / Completed
CompletedNCT04466046
The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 68 (actual)
- Sponsor
- Daegu Catholic University Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Nausea and vomiting after surgery are one of the complications that occur after general anesthesia, and the frequency is reported to range from 10% to 80% in the high-risk group. Several studies have introduced drugs and methods to prevent nausea and vomiting after surgery. Among them, midazolam administered before surgery is known to have anti-anxiolytic and sedative effects on the prevention of nausea and vomiting after surgery. It has also been reported to increase its effectiveness when administered with other antiemetic agents. The purpose of this study is to compare the effects of administration of combination with midazolam and different antiemetic agents on the prevention of postoperative nausea and vomiting in high-risk patients.
Detailed description
This prospective study evaluates female, nonsmoking patients undergoing laparoscopic cholecystectomy. The patients are divided into those with and without postoperative nausea and vomiting. The purpose of this study is to compare and observe the effect of administration of midazolam and two different antiemetics on prevention of postoperative nausea and vomiting. 0.05mg/kg of midazolam is administered intravenously 10 minutes before surgery as a pretreatment. 0.3mg ramosetron is administered intravenously right before the end of surgery and 0.075mg palonosetron is administered intravenously immediately after induction of anesthesia. The incidence of PONV, severity of nausea, use of rescue antiemetics, and pain severity was evaluated at 2 hours, 24hours, and 48 hours after surgery.
Conditions
Timeline
- Start date
- 2019-09-04
- Primary completion
- 2020-06-30
- Completion
- 2020-06-30
- First posted
- 2020-07-10
- Last updated
- 2022-11-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04466046. Inclusion in this directory is not an endorsement.